

CLAIMS

1. A pharmaceutical composition comprising a PPAR α agonist; and a suitable excipient.

2. The pharmaceutical composition according to claim 1 wherein
5 the PPAR α agonist is selected from the group consisting of WY-14643, clofibrate, benzafibrate, fenofibrate, GW409544 and BM-17.0744.

3. A method of treating or preventing a PPAR α -related disease comprising:

administering an effective amount of a pharmaceutical composition
10 comprising a PPAR α agonist and a suitable excipient to an individual in need of such treatment.

4. The method according to claim 3 wherein the PPAR α -related disease is selected from the group comprising: restenosis, chronic renal failure, atherosclerosis, hypertension, diabetes, benign hyperplastic prostate, prostate
15 cancer, rheumatoid arthritis, asthma, stress-induced inflammation, hypoxia, fibrotic disease, skin wound healing, keloids, Crohn's disease, ulcerative colitis, endometriosiis, fibromatosis, pulmonary hypertension, cardiac hypertrophy, congestive heart failure and leiomyomas (fibroids).

5. A kit comprising a PPAR α agonist for treating or preventing a
20 PPAR α -related disorder and instructions for administration of said PPAR α agonist for the treatment of an injury-related disorder.

6. The kit according to claim 5 wherein the PPAR α -related disease is selected from the group comprising: restenosis, chronic renal failure, atherosclerosis, hypertension, diabetes, benign hyperplastic prostate, prostate
25 cancer, rheumatoid arthritis, asthma, stress-induced inflammation, hypoxia, fibrotic disease, skin wound healing, keloids, Crohn's disease, ulcerative colitis, endometriosiis, fibromatosis, pulmonary hypertension, cardiac hypertrophy, congestive heart failure and leiomyomas (fibroids).